More competition in the drug industry would prevent situations like the big price hike in Mylan's (MYL) EpiPens, according to TheStreet's Jim Cramer. He says pharmaceutical companies know they can raise drug prices when competition is scarce. On Thursday, Mylan's CEO discussed the EpiPen price increase on CNBC. Cramer said the honorable thing for CEO Heather Bresch to do would have been to announce a cut in EpiPen prices, which did not happen.
Scroll to Continue